Please find enclosed intimation.

4th August, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Dear Sir/Madam, Sub: Update on USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 10th February, 2026 regarding the Pre-Approval Inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals, Inc. ("InvaGen"), a wholly-owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, we hereby inform you that InvaGen has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection. Please take the above information on record. Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Prepared by: Chirag Hotchandani Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380